Results 111 to 120 of about 34,967 (216)

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Frontiers in Cardiovascular Medicine
ObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj   +1 more source

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 762-773, September 2026.
Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Nihan Izat, Haribhau Kangne, Rasmus Jansson‐Löfmark, Jens K. Hertel, Amin Rostami‐Hodjegan, Ida Robertsen, Aleksandra Galetin   +6 more
wiley   +1 more source

Rivaroxaban administration after acute ischemic stroke: The RELAXED study.

PLoS ONE, 2019
The efficacy of early anticoagulation in acute stroke with nonvalvular atrial fibrillation (NVAF) remains unclear. We performed a study to evaluate the risk of recurrent ischemic stroke (IS) and major bleeding in acute IS patients with NVAF who started ...
Masahiro Yasaka, Kazuo Minematsu, Kazunori Toyoda, Etsuro Mori, Teruyuki Hirano, Toshimitsu Hamasaki, Hiroshi Yamagami, Takehiko Nagao, Shinichi Yoshimura, Shinichiro Uchiyama, RELAXED study group   +10 more
doaj   +1 more source

Cardiovascular Diseases: Exploring Epidemiology, Pathophysiology, Risk Factors, and Medicinal Plant‐Based Therapies: A Narrative Review

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, encompassing coronary artery disease, hypertension, heart failure, and cerebrovascular disorders. The global burden of CVD continues to rise, driven by complex interactions among endothelial dysfunction, oxidative stress, inflammation,
Nawfal Hasan Siam, Umme Halima Mithila, Sadia Alam Tisha, Hridoy Saha, Ayesha Binte Mahbub, Farhan Nizam, Johirul Islam, Noushin Tabasumma, Md. Mazharul Islam Chowdhury   +8 more
wiley   +1 more source

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

, 2012
Alexander GG Turpie,1 André C Schmidt,2 Reinhold Kreutz,3 Michael R Lassen,4 Waheed Jama,1,2 Lorenzo Mantovani,5 Sylvia Haas61Department of Medicine, Hamilton Health Sciences, General Division, Ontario, Canada; 2Bayer Healthcare ...
Kreutz R, Mantovani L, Turpie AG, Schmidt AC, Jamal W, Lassen MR, Haas S   +6 more
core  

Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence, Risk Factors at a Tertiary Care Hospital in Nepal: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Epistaxis is a common complication associated with oral anticoagulant and antiplatelet therapies, often leading to significant morbidity. In recent years, the incidence of cardiovascular disease in Nepal has risen dramatically, driving a widespread use of these medications and heightened concerns regarding bleeding ...
Shiv Kumar Sah, Ashok Kumar Gupta, Sanjaya Acharya, Suraj Kumar Thakur, Rajkumar Chaudhary, Shiva Pandeya, Arjun Budthapa, Vijaya K. C., Sajish Khadgi, Manjita Bajracharya   +9 more
wiley   +1 more source

Assessing the link between rivaroxaban concentration and the onset of renal impairment in elderly patients: A retrospective observational study

Asian Journal of Medical Sciences
Background: Rivaroxaban is a widely used anticoagulant, but its impact on renal function, particularly at varying plasma concentrations, remains a critical area of investigation.
Motakatla Usha Rani , Chitra Karuppiah , Penupothu Sree Nagamani   +2 more
doaj   +1 more source

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World

American Journal of Hematology, Volume 101, Issue 9, Page 2463-2468, September 2026.
Rodrigo Ortega Perez, Luis Manuel Domínguez Rodríguez, Francisca Ferrer‐Marín, Beatriz Cuevas Ruíz, Clara Martínez Valverde, Patricia Vélez Tenza, María Isabel Mata Vázquez, Adrián Segura Díaz, María Laura Fox, Elvira Mora, Manuel Mateo Pérez Encinas, Mercedes Gasior Kabat, Gonzalo Carreño‐Tarragona, Rafael Andrés del Orbe, Gonzalo Caballero‐Navarro, Elena Magro Mazo, Ana Pardo Sanz, José Luis Zamorano Gómez, Alberto Álvarez Larrán, Valentín Garcia‐Gutierrez   +19 more
wiley   +1 more source

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition

International Journal of Cancer, Volume 159, Issue 5, Page 1337-1344, 1 September 2026.
Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell, Julian Kött, Noah Zimmermann, Greta Ancker, Alexander T. Bauer, Daniel J. Smit, Glenn Geidel, Julian C. Gerwers, Thomas Renné, Sebastian A. Wohlfeil, Jochen Utikal, Stefan W. Schneider, Christoffer Gebhardt   +12 more
wiley   +1 more source

Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 9, September 2026.
The clinical manifestations of PFO. Although the majority of PFOs are benign and asymptomatic, they can present with a variety of clinical manifestations, or coexisting with other diseases and aggravating their symptoms, including cerebral diseases (such as CS, epilepsy, TIA, or migraine), systemic embolism (such as embolism in renal artery, coronary ...
Linlin Meng, Xiaotong Zhang, Guangrui Sun, Honggang Dai, Xiao Meng, Cheng Zhang, Yun Zhang   +6 more
wiley   +1 more source